
DBV Technologies Unveils Plan for ADS Ratio Change in 2024: A Strategic Move for Future Growth
DBV Technologies Announces Plan to Implement ADS Ratio Change Châtillon, France, November 11, 2024 DBV Technologies, a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, has announced plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares. The current…